A Phase II Study of CRT Combined With QL1706 in ESCC Patients

This study is testing a combination of chemoradiation (chemotherapy plus radiation at the same time) with a new immunotherapy drug called QL1706 in patients with advanced esophageal squamous cell cancer that cannot be surgically removed. Immunotherapy helps the immune system find and attack cancer cells. **You may be eligible if...** - You are between 18 and 75 years old - You have advanced esophageal squamous cell carcinoma confirmed by biopsy - Your cancer is unresectable (cannot be surgically removed) at stage II–IVa - You have not had previous esophageal cancer surgery - You have at least one measurable tumor on scans - You volunteer to participate and sign informed consent **You may NOT be eligible if...** - You have had previous esophageal surgery - You have a fistula (abnormal tunnel) caused by your tumor - You are at high risk of gastrointestinal bleeding, esophageal fistula, or perforation - You have lost more than 10% of your body weight in the past 2 months without improvement - You had major surgery or significant injury within the past 4 weeks Talk to your doctor to see if this trial is right for you.